MDT

85.6

-1.76%↓

A

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

A

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

A

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

A

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

A

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Search

Ascendis Pharma A-S ADR

Cerrado

SectorSanidad

241.59 -0.04

Resumen

Variación precio

24h

Actual

Mínimo

236.04

Máximo

243.11

Métricas clave

By Trading Economics

Ingresos

28M

-33M

Ventas

32M

245M

Margen de beneficios

-13.56

Empleados

1,189

EBITDA

68M

15M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+22.72% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.7B

15B

Apertura anterior

241.63

Cierre anterior

241.59

Noticias sobre sentimiento de mercado

By Acuity

54%

46%

303 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 abr 2026, 23:14 UTC

Ganancias

Battery Maker CATL First-Quarter Net Rose on Strong Demand

15 abr 2026, 23:14 UTC

Ganancias

Battery Maker CATL First Quarter Net Rose On Strong Demand

15 abr 2026, 17:13 UTC

Principales Movimientos del Mercado

Tesla Shares Rise on Completion of AI5 Chip Design Process

15 abr 2026, 23:39 UTC

Charlas de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

15 abr 2026, 23:35 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

15 abr 2026, 22:41 UTC

Ganancias

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

15 abr 2026, 22:38 UTC

Ganancias

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

15 abr 2026, 22:15 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 abr 2026, 22:15 UTC

Charlas de Mercado

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

15 abr 2026, 22:14 UTC

Ganancias

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

15 abr 2026, 22:12 UTC

Ganancias

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

15 abr 2026, 22:11 UTC

Ganancias

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

15 abr 2026, 22:11 UTC

Ganancias

Lens Technology Swings to Loss in 1Q>300433.SZ

15 abr 2026, 22:07 UTC

Ganancias

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

15 abr 2026, 21:34 UTC

Adquisiciones, fusiones, absorciones

Skild AI Acquires Zebra Technologies' Robotics Automation Business

15 abr 2026, 21:29 UTC

Acciones populares

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

15 abr 2026, 20:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

15 abr 2026, 20:30 UTC

Ganancias

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

15 abr 2026, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

15 abr 2026, 20:06 UTC

Charlas de Mercado

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

15 abr 2026, 19:46 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

15 abr 2026, 19:25 UTC

Charlas de Mercado

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

15 abr 2026, 19:00 UTC

Charlas de Mercado

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

15 abr 2026, 18:58 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

15 abr 2026, 18:11 UTC

Adquisiciones, fusiones, absorciones

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

15 abr 2026, 17:45 UTC

Adquisiciones, fusiones, absorciones

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

15 abr 2026, 16:58 UTC

Ganancias

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

15 abr 2026, 16:52 UTC

Ganancias

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

15 abr 2026, 16:46 UTC

Charlas de Mercado
Noticias de Eventos Importantes

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

15 abr 2026, 16:37 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR previsión

Precio Objetivo

By TipRanks

22.72% repunte

Estimación a 12 Meses

Media 296.62 USD  22.72%

Máximo 342 USD

Mínimo 255 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

13

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

303 / 348 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat